Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Topics

Unresectable hepatocellular carcinoma · HIMALAYA study · Durvalumab plus tremelimumab · tremelimumab · durvalumab · sorafenib · Overall survival · Phase III clinical trial · Immune checkpoint inhibitor therapy · CTLA-4 inhibition · PD-1/PD-L1 inhibitor · combination immunotherapy · Long-term survival · 4-year overall survival · hazard ratio · disease control · Long-term survival · Treatment-related adverse events · subsequent anticancer therapy · First-line treatment · Noninferiority trial · safety profile · subgroup analysis · Randomized controlled trial · survival rate · late-onset safety signals · clinically relevant subgroups · median follow-up · Systemic therapy · hepatocellular carcinoma subgroups